Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zonghui Hu

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Nature Medicine|December 10, 2021
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaquesPeng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
The Journal of Infectious Diseases|February 18, 2026
Plasma biomarkers of immunothrombosis are independently associated with death in patients with COVID-19 on ECMOAndrew P Platt, Viviane Callier, Alison Grazioli, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Nature Medicine|December 10, 2021
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaquesPeng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
The Journal of Infectious Diseases|February 18, 2026
Plasma biomarkers of immunothrombosis are independently associated with death in patients with COVID-19 on ECMOAndrew P Platt, Viviane Callier, Alison Grazioli, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
Pageof 8